Haleos Labs

Haleos is a biotechnology company pioneering the next generation of targeted protein degradation (TPD) therapies. Founded by Dr. David Liu and Dr. Andrew Yao, the company focuses on discovering novel molecular glues and bifunctional degraders that can recruit a broader array of E3 ligases than current technologies. This approach aims to overcome the limitations of existing TPD methods, such as resistance and limited tissue distribution, by accessing previously undruggable protein targets. Haleos is currently operating in the pre-clinical stage, leveraging its proprietary discovery platform to build a robust pipeline primarily focused on oncology and immunology. The company is backed by leading life science investors and is headquartered in the biotech hub of Cambridge, Massachusetts.